Home » HCV » Page 2

Tag Archives: HCV

The EpiPen Episode, an Epitaph on Epinephrine as we know it, an Epilogue and an Epiphany

Posted on by — No Comments ↓

For a good long time, economists have been thinking about the reimbursement quandary for antibiotics, esp. antibacterials. They are just too cheap, right?  Well, with the exception of HCV and some newer HIV drugs, few compounds have ever reached the stratospheric prices that oncology drugs or TNF alpha inhibitors command. Continue reading The EpiPen Episode, an Epitaph on Epinephrine as we know it, an Epilogue and an Epiphany→

Discontinued But Not Forgotten: HCV Drugs That Did Not Make It

Posted on by — No Comments ↓

I find it useful to look back and review drug candidates that were stopped in development.  In case of insufficient efficacy, i.e., not enough of a VL reduction or early viral rebound, everyone can sympathize with the decision to discontinue a drug. More importantly, we want to learn about the Continue reading Discontinued But Not Forgotten: HCV Drugs That Did Not Make It→

2014: The Year That Changed The Landscape of HCV Therapy

Posted on by — No Comments ↓

It was déjà vu all over again, albeit compressed in time: when the race started to replace PegIFN+RBV for the treatment of HCV infection, the learnings from HIV drug development and the lessons with HAART provided an excellent template for quick and efficient development. There was early consensus that a search Continue reading 2014: The Year That Changed The Landscape of HCV Therapy→